Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.55 EUR
−33.43 M EUR
9.06 K EUR
57.07 M
About GlycoMimetics, Inc.
Sector
CEO
Harout Semerjian
Headquarters
Rockville
Website
Founded
2003
FIGI
BBG005KLZV02
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GKO is 0.29 EUR — it has decreased by −6.81% in the past 24 hours. Watch GLYCOMIMETICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange GLYCOMIMETICS INC stocks are traded under the ticker GKO.
GKO stock has fallen by −15.76% compared to the previous week, the month change is a 88.46% rise, over the last year GLYCOMIMETICS INC has showed a −78.85% decrease.
GKO stock is 1.03% volatile and has beta coefficient of −0.35. Track GLYCOMIMETICS INC stock price on the chart and check out the list of the most volatile stocks — is GLYCOMIMETICS INC there?
Today GLYCOMIMETICS INC has the market capitalization of 19.59 M, it has decreased by −22.59% over the last week.
Yes, you can track GLYCOMIMETICS INC financials in yearly and quarterly reports right on TradingView.
GLYCOMIMETICS INC is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
GKO net income for the last quarter is −8.82 M EUR, while the quarter before that showed −9.43 M EUR of net income which accounts for 6.38% change. Track more GLYCOMIMETICS INC financial stats to get the full picture.
No, GKO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 28, 2024, the company has 35.00 employees. See our rating of the largest employees — is GLYCOMIMETICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GLYCOMIMETICS INC EBITDA is −32.99 M EUR, and current EBITDA margin is −391.22 K%. See more stats in GLYCOMIMETICS INC financial statements.
Like other stocks, GKO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GLYCOMIMETICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GLYCOMIMETICS INC technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GLYCOMIMETICS INC stock shows the strong sell signal. See more of GLYCOMIMETICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.